How Juno Therapeutics’ Cellular Immunotherapy Portfolio Could Help Celgene – Market Realist
Market Realist |
How Juno Therapeutics' Cellular Immunotherapy Portfolio Could Help Celgene
Market Realist (To know more on Novartis' Kymriah, please refer to Market Realist's “How Is Novartis's Kymriah Positioned for 2018?“) In October 2017, the FDA approved Gilead Sciences' Yescarta for the treatment of certain types of non-Hodgkin lymphoma. The … Here's Why Fate Therapeutics Rose as Much as 18% Today Juno Therapeutics (JUNO) Lowered to Sell at Zacks Investment Research Celgene's $9B Buyout of Juno to Boost Company's Immuno-Oncology Portfolio |
